CTLA4 and gastric cancer: Immunotherapy analysis demonstrated that in samples that were CTLA4-negative (CTLA4_neg) and PD1-negative (PD1_neg), the group with low expression demonstrated significantly higher IPS compared to the group with high expression (Figures 7B, C), suggesting that patients with GC with low CPZ expression may obtain better immunotherapy results.